
Unicycive Therapeutics (UNCY) Stock Forecast & Price Target
Unicycive Therapeutics (UNCY) Analyst Ratings
Bulls say
Unicycive Therapeutics is in a strong financial position with simplified cap table and significant cash reserve to support launch preparations, which are ongoing despite the delay caused by FDA’s Complete Response Letter. The company’s oxylanthanum carbonate has the potential to generate significant revenue in the hyperphosphatemia market, with peak risk-adjusted U.S. net sales projected to reach approximately $400 million in 2028. However, there are significant clinical and regulatory risks associated with the drug, as any negative outcomes could significantly impact the potential value of the program. The company’s success depends on successful execution and timely approval from the FDA, along with a successful launch in the market.
Bears say
Unicycive Therapeutics is facing significant regulatory and reimbursement risks, as the FDA has not yet inspected the third-party manufacturing site responsible for receiving a second Complete Response Letter for its phosphate binder OLC. This delay in approval has pushed back the potential launch of OLC, resulting in a decrease in our price target to $15 per share. Additionally, the company has a history of operating losses and may need to raise additional capital, which could dilute current shareholders. Furthermore, commercial adoption of OLC may be hindered by challenges in obtaining proper reimbursement and competition from other approved binders.
This aggregate rating is based on analysts' research of Unicycive Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Unicycive Therapeutics (UNCY) Analyst Forecast & Price Prediction
Start investing in Unicycive Therapeutics (UNCY)
Order type
Buy in
Order amount
Est. shares
0 shares